InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $17.850 0.4 (2.29%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6,067 Application for quotation of securities - TLX 14 Sep 2026 4:41PM $16.340 $17.850 risen by 9.24%
$6,067 FDA Approves Telix Brain Cancer Imaging Drug Pixclara 14 Sep 2026 8:21AM $15.670 $17.850 risen by 13.91%
$6,067 Telix Completes Enrollment in Phase 3 BiPASS Study 2 Sep 2026 8:16AM $15.270 $17.850 risen by 16.90%
$6,067 Telix Appoints David Gill as Chair 1 Sep 2026 8:18AM $15.360 $17.850 risen by 16.21%
$6,067 Telix HY26 Results Presentation 20 Aug 2026 8:42AM $16.840 $17.850 risen by 6%
$6,067 Telix HY26 Results Announcement 20 Aug 2026 8:41AM $16.840 $17.850 risen by 6%
$6,067 Telix HY26 Appendix 4D and Interim Report 20 Aug 2026 8:40AM $16.840 $17.850 risen by 6%
$6,067 Telix H1 2026 Results - Investor Webcast Notification 31 Jul 2026 8:30AM $14.070 $17.850 risen by 26.87%
$6,067 Change in substantial holding 24 Jul 2026 8:21AM $15.170 $17.850 risen by 17.67%
$6,067 Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress 21 Jul 2026 8:26AM $15.100 $17.850 risen by 18.21%
$6,067 Notification of cessation of securities - TLX 10 Jul 2026 8:24AM $16.940 $17.850 risen by 5.37%
$6,067 Notification regarding unquoted securities - TLX 10 Jul 2026 8:24AM $16.940 $17.850 risen by 5.37%
$6,067 Application for quotation of securities - TLX 10 Jul 2026 8:24AM $16.940 $17.850 risen by 5.37%
$6,067 Change in substantial holding 8 Jul 2026 5:49PM $16.580 $17.850 risen by 7.66%
$6,067 Ceasing to be a substantial holder 3 Jul 2026 1:36PM $16.710 $17.850 risen by 6.82%
$6,067 FDA Alignment to Advance ProstACT Global Phase 3 Trial 2 Jul 2026 10:07AM $17.060 $17.850 risen by 4.63%
$6,067 Change in substantial holding 1 Jul 2026 12:38PM $17.225 $17.850 risen by 3.63%
$6,067 Change in substantial holding 1 Jul 2026 8:17AM $16.580 $17.850 risen by 7.66%
$6,067 Becoming a substantial holder 30 Jun 2026 5:24PM $16.580 $17.850 risen by 7.66%
$6,067 Becoming a substantial holder 25 Jun 2026 8:16AM $15.730 $17.850 risen by 13.48%
$6,067 Ceasing to be a substantial holder 23 Jun 2026 5:32PM $14.560 $17.850 risen by 22.60%
$6,067 Appendix 3Y Change in Director Interest D Gill 17 Jun 2026 8:24AM $13.850 $17.850 risen by 28.88%
$6,067 Change in substantial holding 9 Jun 2026 8:13AM $13.310 $17.850 risen by 34.11%
$6,067 Notification regarding unquoted securities - TLX 1 Jun 2026 3:26PM $13.035 $17.850 risen by 36.94%
$6,067 Appendix 3Y Change in Director Interest - C Behrenbruch 1 Jun 2026 3:20PM $13.035 $17.850 risen by 36.94%

1 - 25 of 955 results

Page 1 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.